

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID579]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Scoping workshop attendees agreed that it was important to consider those who may have difficulty self-administering subcutaneous treatments. However it was agreed that there are already processes in place in clinical practice for people who are unable to self-administer subcutaneous treatments.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No equalities issues were raised in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee noted that some people may have physical, sensory or learning disabilities or communication difficulties that could affect their responses to components of the Psoriatic Arthritis Response Criteria (PsARC). It concluded that this should be taken into account when using the PsARC. The draft recommendations include this consideration.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Some people may have physical, sensory or learning disabilities or communication difficulties that could affect their responses to components of the PsARC, which may affect the decision to continue treatment with certolizumab pegol and secukinumab (assessed at 12 weeks and 16 weeks respectively). The draft recommendations state that clinicians should take this into account when using the PsARC.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No, none identified.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The committee's considerations of equality issues are described in section 4.21 of the appraisal consultation document. The recommendation to take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC is described in section 1.4.

Approved by Associate Director (name): Helen Knight

Date: 01/11/2016

Consultation 2

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have not changed.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations have not changed.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations have not changed.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee's considerations of equality issues are described in section 4.21 of the appraisal consultation document. The recommendation to take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC is described in section 1.4.

Approved by Associate Director (name): Helen Knight

Date: 22/12/2017

Final appraisal determination

(when an ACD issued)

6. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No.

7. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have not changed.

8. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on

people with disabilities because of something that is a consequence of the disability?

The recommendations have not changed.

9. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations have not changed.

10. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee's considerations of equality issues are described in section 4.22 of the final appraisal determination. The recommendation to take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC is described in section 1.4.

Approved by Associate Director (name): Helen Knight

Date: 06/04/2017